Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
The Journal of Clinical Investigation
|
December 1, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion
Fen Ma, Sen Chen, Luigi Cecchi, et al.
Cell
|
August 21, 2024
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, et al.
Cancer
|
January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Rana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Biorxiv : the Preprint Server for Biology
|
August 14, 2023
A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, et al.
JCO Precision Oncology
|
September 19, 2019
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
S Thomas Hennigan, Shana Y Trostel, Nicholas T Terrigino, et al.
Biorxiv : the Preprint Server for Biology
|
September 15, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Prathyusha Konda, Cary N Weiss, Yantong Cui, et al.
European Urology
|
February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Paul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
The Journal of Urology
|
March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
Rana R McKay, Wanling Xie, Huihui Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2020
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Shivanshu Awasthi, Anders Berglund, Julieta Abraham-Miranda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
The Journal of Clinical Investigation
|
December 1, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion
Fen Ma, Sen Chen, Luigi Cecchi, et al.
Cell
|
August 21, 2024
A genetic basis for sex differences in Xp11 translocation renal cell carcinoma
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, et al.
Cancer
|
January 1, 2024
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial
Rana R McKay, Wanling Xie, Xiaoyu Yang, et al.
Biorxiv : the Preprint Server for Biology
|
August 14, 2023
A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma
Mingkee Achom, Ananthan Sadagopan, Chunyang Bao, et al.
JCO Precision Oncology
|
September 19, 2019
Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer
S Thomas Hennigan, Shana Y Trostel, Nicholas T Terrigino, et al.
Biorxiv : the Preprint Server for Biology
|
September 15, 2025
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Prathyusha Konda, Cary N Weiss, Yantong Cui, et al.
European Urology
|
February 11, 2026
FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide
Paul L Nguyen, Marisa A Kollmeier, Dana E Rathkopf, et al.
The Journal of Urology
|
March 8, 2021
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer
Rana R McKay, Wanling Xie, Huihui Ye, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 10, 2020
Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Shivanshu Awasthi, Anders Berglund, Julieta Abraham-Miranda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Page
of 6